Lumipulse® G PIVKA-II
Getting a better view on liver cancer
Immunoreaction cartridges for in vitro diagnostic (IVD) use with the LUMIPULSE G System for the quantitative measurement of protein induced vitamin K absence or antagonist-II (PIVKA-II) in serum.
The assay utilises proven CLEIA (ChemiLuminescent Enzyme Immunoassay) technology with results that are available in up to 35 minutes.
Product number 233184
Product number 233191
Click here to navigate
- Details
- Conditions of sale
- Documentation
- Insights
- Related products
- Product inquiry
-
Details
Product benefits
- Allows stratification of patients on transplant waiting list.
- Predicts recurrence of HCC.
-
Complementary to AFP for improved detection of (early) HCC.
Complete Solution:-
CE-marked
-
Only assay available on an automated platform (LUMIPULSE G1200)
-
Oncology menu available for routine, specialized and unique markers
-
Chemiluminescent assay
-
Calibrators and controls available
Different clinical applications:-
Monitoring: Correlation with microvascular invasion, recurrence and tumor size
-
Diagnosis: Complementary to AFP for the improved detection of HCC
Clinical backgroundHepatocellular carcinoma (HCC) is one of the most common cancers worldwide with a high rate of mortality and an increasing incidence.
The most common causes of HCC are either a viral hepatitis infection (hepatitis B or C) or cirrhosis (alcoholism being the most common cause of hepatic cirrhosis).
The starting point in the diagnostic surveillance of at risk patients is ultrasound.
In a second stage this can be completed with the measurement of a tumor marker called α-fetoprotein (AFP).
Since ultrasound has a poor performance in cirrhotic patients and is also operator dependent, further characterization by CT or MRI is often required.
As it is important to detect HCC at an early stage when the disease is still curable, biomarkers can complete the diagnosis obtained with ultrasound before moving on to the more expensive MRI.
Biomarkers can also be used to better stratify patients on the liver transplant waiting list.
Additionally, the risk of recurrence of HCC after transplantation can be assessed by monitoring patients with biomarkers.
Assay technology
CLEIA - ChemiLuminescent Enzyme Immunoassay
See the LUMIPULSE G1200 working in this video:
-
Conditions of sale
To read the end user conditions of sale for this product please visit our Resource center.
-
Documentation
Browse regulatory documents for this product
Create a (free!) eServices account and start browsing all regulatory documentation right away.
Other documents
FilePIVKA-II biomarker information physician leaflet.pdf (pdf, 2.09 mb)Get access to this section and more
Create a free eServices account now and instantly access multiple digital resources:
- Regulatory product documentation
- Selected scientific posters
- Product leaflets
- How-to videos and more…
-
Insights
PIVKA-II, a biomarker of liver cells for the management of hepatocellular carcinoma (HCC)
PIKVA-II (Protein Induced Vitamin K Absence or Antagonist-II) is an immature form of prothrombin also known as DCP (Des-gamma-Carboxy Prothrombin)...
Sep 25, 2015
-
Related products
-
Product inquiry